| Literature DB >> 28604729 |
David Brocks1, Christopher R Schmidt1, Michael Daskalakis1,2, Hyo Sik Jang3, Nakul M Shah3, Daofeng Li3, Jing Li3, Bo Zhang3, Yiran Hou3, Sara Laudato1, Daniel B Lipka1, Johanna Schott4, Holger Bierhoff5, Yassen Assenov1, Monika Helf1, Alzbeta Ressnerova1, Md Saiful Islam1, Anders M Lindroth1, Simon Haas6, Marieke Essers6, Charles D Imbusch7, Benedikt Brors2,7, Ina Oehme8, Olaf Witt2,8, Michael Lübbert2,9, Jan-Philipp Mallm10, Karsten Rippe10, Rainer Will11, Dieter Weichenhan1, Georg Stoecklin3, Clarissa Gerhäuser1, Christopher C Oakes1, Ting Wang3, Christoph Plass1,2,11.
Abstract
Several mechanisms of action have been proposed for DNA methyltransferase and histone deacetylase inhibitors (DNMTi and HDACi), primarily based on candidate-gene approaches. However, less is known about their genome-wide transcriptional and epigenomic consequences. By mapping global transcription start site (TSS) and chromatin dynamics, we observed the cryptic transcription of thousands of treatment-induced non-annotated TSSs (TINATs) following DNMTi and HDACi treatment. The resulting transcripts frequently splice into protein-coding exons and encode truncated or chimeric ORFs translated into products with predicted abnormal or immunogenic functions. TINAT transcription after DNMTi treatment coincided with DNA hypomethylation and gain of classical promoter histone marks, while HDACi specifically induced a subset of TINATs in association with H2AK9ac, H3K14ac, and H3K23ac. Despite this mechanistic difference, both inhibitors convergently induced transcription from identical sites, as we found TINATs to be encoded in solitary long terminal repeats of the ERV9/LTR12 family, which are epigenetically repressed in virtually all normal cells.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28604729 PMCID: PMC6005702 DOI: 10.1038/ng.3889
Source DB: PubMed Journal: Nat Genet ISSN: 1061-4036 Impact factor: 38.330